|
Beth E. Arnold
Partner
Boston
Beth Arnold, a partner in the firm's intellectual property practice, is a U.S. registered patent attorney with some 20 years of experience in obtaining worldwide patent protection for pharmaceutical and biotechnology products. She has received recognition as a leading IP practitioner from Chambers USA, The Best Lawyers in America, Massachusetts SuperLawyers and Global Counsel 3000. Her clients include top-tier pharmaceutical companies, as well as public and private biotechnology companies and medical research institutes. In addition to protecting the intellectual assets of these clients, Beth prepares and negotiates agreements that help them develop and commercialize new pharmaceutical and biotechnology products.
As part of her full range of patent counseling services, Beth drafts non-infringement, invalidity and clearance opinions. On the transactional side, she performs patent due diligence in connection with public or private financings, mergers and acquisitions and other business combinations. An experienced player in the life sciences field, Beth served as in-house patent counsel at Genzyme Corporation and as Technology Transfer Officer at the Massachusetts General Hospital before joining Foley Hoag.
Bars and Court Admissions
Massachusetts
U.S. Patent & Trademark Office (Agency)
U.S. District Court for the District of Massachusetts
professional / civic involvement
Women Entrepreneurs in Science and Technology (WEST), Board of Directors
The Biotechnology Industry Organization (BIO), Member
The Massachusetts Biotechnology Council (MBC), Member
The Licensing Executive Society (LES), Member
American Intellectual Property Law Association (AIPLA), Member
Boston Patent Law Association (BPLA), Member
American Bar Association (ABA), Member
Boston Bar Association (BBA), Member
SPEECHES AND CONFERENCES
AIPLA Spring Meeting, "A Practitioner's Guide to Petitions to Make Special: How to Effectively Expedite Examination of Your Patent Application," May 11, 2005
Springboard Enterprise Venture Capital Forum Alumni Celebration, "Partnering for Growth - Not Creating Competitors," March 16, 2005
LES 40th Annual Meeting, "The Negotiation and Drafting of Collaborative Drug Development Agreements," October 18, 2004
IBC Life Sciences Protecting Biotech Inventions Conference, "Patent Protecting Biological Processes in the U.S.," Zurich Switzerland, September 21-23, 2004
MassMEDIC: Managing Your MedTech Company's Intellectual Property, "Patent Claim Strategies to Maximize Value," June 15, 2004
BioIT World 2004 Annual Meeting, Boston, MA, "The Druggable Genome: What to Patent?," March 2004
The Licensing Executive Society (LES) Annual Meeting, Chicago, IL, "Patents and Biological Materials: Do You Really Own What You Think?", September 2002
Compaq Computer Corporation and Whitehead Institute Center for Genome Research sponsored seminar, 21st Century Life Science Technology Revolution, "Patenting Genes and Genetic Research Tools," June 10-12, 2002
Boston College Health Law Series, "Commercializing Medical Technologies," October 2000
American Society of Law, Medicine & Ethics, Boston, MA, "The Impact of Patent Law on the Dissemination of Genetic Tests," September 2000
McKinsey & Company Annual Healthcare Meeting, Boca Raton, FL, "Patent Considerations Pertaining to Genomic Technologies," February 2000
publications
A Practitioner's Guide to Petitions to Make Special, AIPLA Spring Meeting (May 11, 2005)
Top five things to consider when negotiating an R&D partnership, MASS HIGH TECH (January 17-23, 2005)
Biogenerics may be inevitable, but will the feds be ready? BOSTON BUSINESS JOURNAL (March 2004)
Getting it Right the First Time: The Biomedical Patent Process, THE ART AND SCIENCE OF PATENT LAW (©Aspatore Books, Inside The Minds series) (2004)
Multiple patents, infringement cases add to cost of drugs, MASS HIGH TECH (March 2003)
Navigating Gene Patent Minefields, BIO IT WORLD (November 2002)
Potential Patent Obstacles on Horizon, BIO IT WORLD (August 2002)
Patenting Genes and Genetic Research Tools: Good or Bad for Innovation? ANNU. REV. GENOMICS HUM. GENET. 3:415-32 (2002)
Bioinformatic patents: Protecting path from data to drugs, BOSTON BUSINESS JOURNAL (June 2001)
Patent Strategies for Protecting Bioinformation: Consider Filing in Computer Examination Group, MIT FORUM REPORTER VOL.19 NO.6 (February 2001)
Chapter 2 - Patent Protection, BIOTECHNOLOGY: LAW, BUSINESS AND REGULATION, (Aspen Law & Business) (2000)
For Biotech Companies, IP Due Diligence Can Be Tricky, THE NATIONAL LAW JOURNAL (March 2000).
|
